POLYCYTHEMIA VERA

This study is testing a combination of drugs to see if it can better prepare patients with advanced blood cancers for a stem cell transplant from a donor. The goal is to control the aggressive cancer cells before the transplant, which may help the new donor cells take hold and fi…

This study allows patients who are already taking the experimental drug bomedemstat for certain rare blood cancers to continue treatment in a long-term follow-up study. The main goal is to collect more information about the drug's safety and how well it continues to work over a l…

This study follows a small group of Italian patients with Polycythemia Vera, a chronic blood cancer, who previously responded well to the drug Ropeginterferon alfa-2b. The goal is to see if the treatment's benefits, like controlling blood counts and preventing complications, are …

This study is testing a modified, gentler two-step method to prepare patients for a stem cell transplant. The goal is to reduce the risk of death from the transplant procedure itself for people with various blood cancers and disorders. Researchers are comparing two lower-intensit…

This study follows 200 adults with polycythemia vera (a blood cancer causing too many red blood cells) who are taking ropeginterferon alfa-2b in real-world German clinics. Researchers will track patients' symptom burden, how well the drug controls blood counts, and safety over th…

This study is testing whether adding a new drug called iadademstat to an existing treatment (ASTX727) works better for controlling advanced blood cancers. It will involve about 62 adults with specific aggressive forms of myeloproliferative neoplasms (MPNs) that have progressed. T…

This study is testing if an investigational drug called Givinostat works better than the current standard treatment, hydroxyurea, for adults with a high-risk form of a blood cancer called polycythemia vera. The goal is to see if Givinostat can more effectively control blood count…

This large Phase 3 trial aims to prevent life-threatening blood clots in people with certain high-risk blood cancers. It will compare newer, more potent blood thinners (apixaban/rivaroxaban) against standard low-dose aspirin in over 1,300 patients. The goal is to see if the newer…

This study is testing whether the drug ruxolitinib can reduce the often severe symptoms experienced by people with low-risk essential thrombocythemia (ET) or polycythemia vera (PV). About 60 participants with significant symptom burdens will take ruxolitinib for at least 6 months…

This study aims to find the best dose of N-Acetylcysteine (N-AC), a common supplement, to help reduce symptoms in people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It will enroll 27 adults with ET, PV, or MF who have significant symptom burden. The main g…

This study is testing whether a curcumin supplement, the active ingredient in turmeric, can reduce inflammation and improve symptoms in people with certain blood cell disorders. Researchers will compare the supplement to a placebo in 30 participants over 12 months. The main goals…

This is a long-term observational study designed to better understand a group of rare, chronic blood cancers called myeloproliferative neoplasms (MPNs). It will follow 5,000 adults in the U.S. for 5-10 years, collecting health records and patient surveys to track symptoms, treatm…

This study aims to learn how a specific type of immune cell, called a monocyte, behaves in people with certain blood cancers. Researchers will collect blood samples from 70 participants who have not yet started treatment for their condition. By analyzing these cells, they hope to…

This study aims to understand why some patients with a blood cancer called essential thrombocythemia (ET) later develop a related cancer called polycythemia vera (PV). Researchers will look back at the medical records of 678 patients to identify risk factors for this change and c…